Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Intarcia’s ITCA 650 unlikely to reach diabetes market following second FDA rejection

Following the news that Intarcia has received a second rejection from the Food and Drug Administration (FDA) regarding its subcutaneous osmotic pump implant, ITCA 650, for type 2 diabetes (T2D) patients; Akash Patel MSc, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “This second FDA rejection leaves the future of Intarcia and its device highly uncertain and it is unlikely that its product will be able to reach the market. Even if ITCA 650 were to make it to market, […]
Read more

75% of nanopharmaceuticals are in clinical development for oncology indications

Of the more than 230 nanopharmaceuticals in clinical development, 75% are for oncology indications, including many hard-to-treat cancers with few treatment options, according to GlobalData, a leading data and analytics company. Nanopharmaceuticals have many physical and biological advantages compared to conventional medicines, including enhanced efficacy and reduced toxicity, which are particularly important in treating cancer patients. One of the main areas of opportunity for nanomedicine to date has been oncology, with high levels of research and development (R&D) activity detected in the field.  GlobalData’s recent report, […]
Read more
,

Coronavirus is prompting suppliers of all shapes and sizes to adapt and support the healthcare system

Thus far, the novel coronavirus (COVID-19) pandemic has surpassed 860,000 confirmed cases globally and while the economic impact is weighing heavily across sectors, organizations are exploring creative ways of how to combat the outbreak. The responses are not only fighting COVID-19, supporting the general public and propping up the healthcare system, but they are also positioning suppliers favorably for the aftermath, says GlobalData, a leading data and analytics company. Organizations across various industries worldwide are pivoting in response to both the clinical and socio-economic effects of COVID-19 to help their local communities. For example, retailers are finding ways of dealing with high demand, […]
Read more

Significant unmet needs remain in the global psoriatic arthritis market

Despite the plethora of drugs currently available for patients with psoriatic arthritis (PsA), several key unmet needs remain, according to GlobalData, a leading data and analytics company. The company’s report: ‘Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028’ reveals that the PsA market was worth over $4.6bn in 2018 and is set to grow to $9.4bn by 2028. Key unmet needs in the disease space include increased clinician awareness, earlier PsA diagnoses, improved drug safety and efficacy across all disease domains […]
Read more

Coronavirus pandemic pushes pharma sales reps deeper into virtual space, says GlobalData

As the novel coronavirus (COVID-19) pandemic continues to spread globally, virtual platforms will experience an extra boost after already having a transformational impact on the entire healthcare landscape even before the outbreak, says GlobalData, a leading data and analytics company. Valentina Gburcik, PhD, Senior Director of Cardiovascular and Metabolic Diseases, Gender Health and Digital at […]
Read more

VIRAL LOAD and COVID-19: how concerned should we be? asks GlobalData

Following a number of recent global news stories about viral load and its impact on Coronavirus (COVID -19) patients; Michael Breen, Director of Infectious Diseases at GlobalData, a leading data and analytics company, offers his view on this phenomena and how concerned we should be about it; “A recent study from China supports a higher viral […]
Read more

New incentives and tax benefits can boost R&D ecosystem for new drug development in India, says GlobalData

India has recently sought feedback from the top pharmaceutical companies to make regulatory changes that offer specific tax benefits for specialized research. With the government’s inclination towards promoting domestic R&D, new incentives and revising the current weighted tax deductions can boost the R&D ecosystem for new drug development in India, says GlobalData, a leading data […]
Read more

High incident cases of invasive pneumococcal disease in India is result of lack of country-wide vaccination, says GlobalData

Invasive pneumococcal disease (IPD) presents a significant public health concern globally. India leads the way with the highest number of diagnosed incident cases of IPD, says GlobalData, a leading data and analytics company. The company’s latest report ‘Pneumococcal Vaccines: Epidemiology Forecast in Asia-Pacific Markets to 2028’, reveals that there were more than two million diagnosed […]
Read more

An estimated 330m people, 15% of the 9MM population, face risk of severe COVID-19, says GlobalData

Following the recent news that the coronavirus (COVID-19) has now spread across 176 countries with approximately 530,000 total confirmed cases worldwide as of 27.03.20; Katie Wrenn, Associate Epidemiologists at GlobalData, a leading data and analytics company, offers her view on the current challenges facing the 9MM: “We now know that severe and critical forms of COVID-19 […]
Read more

Novartis’ Zolgensma expected to generate global sales of $2.5bn by 2025 with new data set to bolster the drug’s uptake, says GlobalData

Novartis recently announced new anticipated long-term positive data for its one-time infusion gene therapy, Zolgensma (onasemnogene abeparvovec-xioi), which is set to help the drug generate global sales of $2.5bn by 2025 and lead the spinal muscular atrophy (SMA) market, says GlobalData, a leading data and analytics company. The data showed significant therapeutic benefit in patients with […]
Read more

Government investment will turnaround active pharmaceutical ingredients industry in India, says GlobalData

Following the news that India has approved US$1.3bn* (INR10Kbn) healthcare package to boost the domestic manufacturing of active pharmaceutical ingredients (API); Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “The package, which is part of a turnaround strategy to reduce India’s dependence on China, will help boost the […]
Read more

Covid-19 outbreak in China threatens biopharma in-house manufacturing, says GlobalData

With several mega cap biopharma companies having their vital manufacturing steps in Chinese facilities, the novel coronavirus (Covid-19) outbreak is putting the complicated global biopharma industry’s supply chain under strain, says GlobalData, a leading data and analytics company. Supply chain problems in China include a largely quarantined workforce, delays in transporting materials and several other […]
Read more

95% of healthcare professionals concerned about coronavirus impact on their companies, says GlobalData

As the number of global coronavirus (COVID-19) cases continues to rise, governments around the world are taking unprecedented measures, to contain the spread and support their economies throughout the outbreak. These measures include billions worth of rescue packages, tax postponements, liquidity injections and interest rate cuts to new lows, says GlobalData, a leading data and analytics company. GlobalData’s […]
Read more

Coronavirus cases in US projected to reach 8.1 million in two weeks, with high-risk scenario totaling more than 21.8 million

Last week, the GlobalData epidemiology team conducted a three-scenario forecast model of the coronavirus (COVID-19) transmission in the US, with the moderate estimate projecting more than 228,500 cases by March 31 and two million in a high-risk scenario. However, developments in the last week have shown the actual increase in confirmed cases was significantly higher […]
Read more
1 … 98 99 100 101 102 … 108